SCHEMBL31349573

SCHEMBL31349573

CC1(O)CC(n2ncc3cc(OCCBr)cc(C(F)(F)F)c32)C1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.32
SCN9A Q15858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26023953 0.91 ACACB (0.33) ARSCN9A
SCHEMBL26030211 0.90 SCN9A (0.33) ARSCN9A
SCHEMBL25905093 0.89 PDK2 (0.34) ARSCN9A
SCHEMBL25904918 0.89 PDK2 (0.34) ARSCN9A
SCHEMBL25905002 0.89 PDK2 (0.34) ARSCN9A
SCHEMBL26042301 0.88 AR (0.31) ARSCN9A
SCHEMBL31349526 0.82 AR (0.32) AR
SCHEMBL25315840 0.81 CA12 (0.38) SCN9A
SCHEMBL31349563 0.81 AR (0.32) AR
SCHEMBL26022450 0.80 MAP3K12 (0.32) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed